Form 4 for ORIC Oric Pharmaceuticals, Inc.
Accepted 2025-10-08 00:00:00 ET · period of report 2025-10-06 · accession 0001608936-25-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-08 | 2025-10-06 | ORIC | Chacko Jacob | Pres AND CEO, Dir | S - Sale | $12.32 | -37.5K | 531.4K | -7% | -$461.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-06 | S | D | 37,461 | $12.32 | 531,419 | D | — | — | (F2) Represents the weighted average share price of an aggregate total of 37,461 shares sold in the price range of $12.07 to $12.59 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. (F3) The Reporting Person also holds restricted stock units (RSUs) representing a contingent right to receive 178,667 shares of ORIC Pharmaceuticals, Inc. Common Stock and stock options to purchase 3,378,000 shares of ORIC Pharmaceuticals, Inc. Common Stock, which were previously reported on Table II and are not included in this number. |